Stayble Therapeutics AB (publ)
STABL.ST
Stockholm Stock Exchange0.21
SEK
- -
- -
Stayble Therapeutics AB (publ)
STABL.ST
(Stockholm Stock Exchange)
Recent
price
0.21
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Stayble Therapeutics AB (publ) (STABL.ST) is a clinical-stage Swedish biotechnology company developing injectable treatments for chronic low back pain caused by disc herniation and degenerative disc disease. The company focuses on STA363, a single X-ray-guided injection into the intervertebral disc that stabilizes the segment, reduces pro-inflammatory leakage and disc instability to provide permanent pain relief; STA363 targets patients unresponsive to conservative therapies like analgesics and physiotherapy, bridging the gap to surgery for millions affected globally, with demonstrated disc volume reduction in preclinical, phase 1b and phase 2b studies for degenerative disc disease and positive phase 1b results for herniated discs. Founded in 2015 and headquartered in Gothenburg, Sweden, Stayble Therapeutics operates primarily in Europe with clinical trials conducted in the Netherlands, Russia and Spain, serving the healthcare sector with a target market of over 24 million new annual patients worldwide who could benefit from its non-surgical disease-modifying therapy. Recent developments include intensified partnering efforts since December 2024 with a renowned transaction advisor to secure licensing deals with mid-sized and large pharmaceutical companies, driven by strong interest following phase 1b data; ongoing confidential discussions with multiple potential partners in February 2025 aimed at advancing STA363 through further clinical development and commercialization; publication of the 2024 annual report and first-quarter 2025 interim report, alongside a paediatric investigation plan waiver granted by the EMA in July 2024.